NXTS — Nexentis Technologies Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1789192 ·
Last close
$1.82
Market Cap
$2.65M
52W High
$119.00
52W Low
$1.80
ADV30
169,081
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,735,000 | -11,145,000 | 18,692,000 | 7,623,000 | 16,910,000 |
| Mar 2026 | 0 | — | -2,277,000 | -6,580,000 | 16,399,000 | 4,299,000 | 3,538,000 |
| Dec 2025 | -68,000 | — | -587,000 | 1,269,000 | 20,405,000 | 3,832,000 | 4,675,000 |
| Sep 2025 | 2,000 | 0 | -1,326,000 | 429,000 | 11,026,000 | 6,044,000 | 2,350,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,429,000
Investing CF
$-2,168,000
Financing CF
$11,068,000
CapEx
$-835,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-59.19
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-56,282,000
Inventory
$16,000
Receivables
$509,000
ST Investments
$1,257,000
EBIT TTM
$-9,737,000
Pretax Income TTM
$-16,434,000
Interest Exp TTM
$10,889,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,366,000 | -4,004,000 | 20,400,000 | 4,675,000 | 16,010,000 | -3,808,000 |
| Dec 2024 | 0 | -3,283,000 | -5,193,000 | 5,465,000 | 892,000 | 4,749,000 | -3,419,000 |
| Dec 2023 | 263,000 | -7,537,000 | -6,522,000 | 7,244,000 | 786,000 | 6,480,000 | -3,234,000 |
| Dec 2022 | 394,004 | -5,819,642 | -5,739,600 | 6,492,213 | 754,872 | 5,846,379 | -5,097,126 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-29,735,000
NetIncome TTM
$-16,027,000
OpCashFlow TTM
—
Assets (Latest)
$18,692,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc. | $2.66M | $1.63 | — |
| BIXT | BIOXYTRAN, INC | $2.66M | $0.02 | — |
| MBIO | MUSTANG BIO, INC. | $2.63M | $0.39 | — |
| EOCN | EoCene Ltd. | $2.63M | $2.46 | — |
| PPBT | PURPLE BIOTECH LTD. | $2.78M | $1.71 | — |
News headlines (Yahoo Finance, 1h cache)
Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
2026-11-17 13:03 · Yahoo
Nexentis Announces Reverse Stock Split
2026-11-05 14:00 · Yahoo
Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
2026-10-29 11:22 · Yahoo
Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
2026-10-26 12:16 · Yahoo
Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
2026-10-12 12:07 · Yahoo
Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud
2026-10-07 14:03 · Yahoo
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
2026-10-07 11:32 · Yahoo
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
2026-09-24 11:50 · Yahoo
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
2026-09-23 11:07 · Yahoo
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
2026-06-29 14:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.